Compare Archer Aviation Inc (ACHR) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer Aviation Inc vs DexCom, Inc. — how do they compare? Archer Aviation Inc trades at $4.89 (market cap $3.76B), while DexCom, Inc. trades at $73.61 (market cap $28.39B). The key difference: DexCom, Inc. is far larger — about 7.6× Archer Aviation Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | DXCM | |
|---|---|---|
Market Cap | $3.76B | $28.39B |
Sector | Industrials | Health |
52-Week High | $13.64 | $89.53 |
52-Week Low | $4.68 | $54.84 |
Enterprise Value | $2.11B | $27.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.
The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.
DXCM trades at $73.57, up 3.26% with a bullish technical outlook and strong fundamental performance. Recent earnings beats and FDA clearances for pediatric use of Stelo CGM support growth. Revenue reached $4.66B in 2025 with net income of $836.30M, reflecting a 19.31% margin. Analyst consensus is strongly bullish with an $83.78 price target.
The outlook remains positive driven by CGM market expansion and international growth, though risks include GLP-1 drug competition and execution in non-insulin markets. Valuation at 31.06 P/E is reasonable for its growth profile, with institutional sentiment favoring further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
